David Critton

Appearances

• Structure-based design of 2-(pyridin-2(1H)-one)indoles as antagonists of the toll-like receptors TLR7 and TLR8 for the treatment of autoimmune diseases
• Turning cold tumors hot: Discovery of novel TLR7 agonists as systemic agent for combination with aPD1 for use in immuno-oncology
• Dimeric antagonists of endosomal toll-like receptors 7, 8 and 9 (TLR7/8/9)
• Optimization of indole-based antagonists of toll-like receptors 7 and 8 (TLR7/8) through C-2 variations
• Optimization of 4H-pyrrolo[3,2-d]thiazole based antagonists of toll-like receptors 7 and 8 (TLR7/8) for the treatment of lupus
• Identification of trisubstituted pyrazoles as potent and selective dual antagonists of toll-like receptors 7 and 8 (TLR 7/8) for the treatment of lupus
• Structure-based design of 2-(pyridin-2(1H)-one)indoles as antagonists of the toll-like receptors TLR7 and TLR8 for the treatment of autoimmune diseases
• Turning cold tumors hot: Discovery of novel TLR7 agonists as systemic agent for combination with aPD1 for use in immuno-oncology
• Discovery of afimetoran, a small molecule dual antagonist of the toll-like receptors 7 and 8 (TLR7/8) advanced to clinical evaluation in patients with lupus
• Exploration of carbazole-based antagonists of toll-like receptors 7 and 8 (TLR7/8) generated via structure-guided evolution of an indole series
• Identification of 2-pyridinyl-indoles as selective dual antagonists of the toll-like receptors 7 and 8 (TLR7/8) for the treatment of autoimmune diseases
• Discovery of selective small-molecule dual antagonists of toll-like receptors 7 and 8 (TLR7/8) through optimization of an indole scaffold and C-2 bicyclic heteroarene substituents